BCG and Kawasaki disease in Mexico and Japan

Dr. Tomisaku Kawasaki was the first to describe BCG reactivation in Kawasaki Disease (KD), and this sign is present in about 30–50% of KD patients. It is a very specific early sign of the disease and although it has been recognized for decades, its pathophysiology continues to be an enigma. Recently...

Full description

Bibliographic Details
Published in:Human Vaccines & Immunotherapeutics
Main Authors: Luisa Berenise Gamez-Gonzalez, Hiromichi Hamada, Beatriz Adriana Llamas-Guillen, Miguel Ruiz-Fernandez, Marco Yamazaki-Nakashimada
Format: Article
Language:English
Published: Taylor & Francis Group 2017-05-01
Subjects:
bcg
kawasaki disease
tuberculid
tokyo172
Online Access:http://dx.doi.org/10.1080/21645515.2016.1267083
Description
Summary:Dr. Tomisaku Kawasaki was the first to describe BCG reactivation in Kawasaki Disease (KD), and this sign is present in about 30–50% of KD patients. It is a very specific early sign of the disease and although it has been recognized for decades, its pathophysiology continues to be an enigma. Recently, Yamada et al. reported a severe BCG reaction with tuberculid in 2 Japanese KD patients. We present 2 cases with KD and severe BCG reaction, one from Japan and the other from Mexico and review the policies of administration of BCG in both countries. The BCG vaccine has a worldwide coverage of 88%. Differences in BCG strains and methods of administration may influence BCG reactions in KD. The BCG reaction in the inoculation site may represent the most useful sign in KD.
ISSN:2164-5515
2164-554X

Similar Items